Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
50 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Pharma Biotech Consultants Europe from Elsene, company number BE0465291083, closed financial year 2025 with a result of € -15,591 after tax. For that financial year Pharma Biotech Consultants Europe recorded a gross margin of € -1,294 and equity of € 19,209. Compared with financial year 2024, the result moved from € -47,120 to € -15,591. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 13, 2026.
€ 19,209
▼ 45% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -15,591
▲ 67 % less loss than in 2024
Profit after tax over the fiscal year.
€ 1,694
▼ 94% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 13,009.
People and assets in 2025
€ 3,162
▼ 76% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 257
▼ 90% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 676
▼ 91% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 98,144 | € 28,694 | € -34,439 | € -1,294 | ▲ € 33,144 |
| Profit after taxes | € 58,966 | € 9,316 | € -47,120 | € -15,591 | ▲ € 31,529 |
| Equity | € 72,604 | € 81,920 | € 34,800 | € 19,209 | ▼ 45% |
| Total debts | € 55,069 | € 40,956 | € 9,802 | € 933 | ▼ 90% |
| Cash | € 75,397 | € 67,825 | € 27,068 | € 1,694 | ▼ 94% |
| Retained profit | € 66,404 | € 75,720 | € 28,600 | € 13,009 | ▼ 55% |
| Balance sheet total | € 127,672 | € 122,876 | € 44,602 | € 20,142 | ▼ 55% |
Key figures of Pharma Biotech Consultants Europe, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Pharma Biotech Consultants Europe?
What happened at Pharma Biotech Consultants Europe in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 15,591. filed late Source: NBB ↗
- New establishment in Nieuwpoort. KBO
- Christian JACQUES became a director. NBB
- Marie-Louise HEIDERSCHEID became a director. NBB
- New establishment in Elsene. KBO
- Start of the company according to the CBE. KBO
In short
From € 58,966 profit in 2022 to € 15,591 loss in 2025.
Paid € 32,690 in corporate taxes since 2022.
Best year ever: 2022, with € 58,966 profit.
A new publication or filing at Pharma Biotech Consultants Europe? We notify you, reason included.
Follow Pharma Biotech Consultants EuropeDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Pharma Biotech Consultants Europe are Christian JACQUES and Marie-Louise HEIDERSCHEID.
Directors
According to the 2025 annual accounts
Christian JACQUES
Director
since 2021
Marie-Louise HEIDERSCHEID
Director
since 2021
Establishments
Establishment units
Physical locations of this company
Louizalaan 287 box 16
1050 Elsene
Zeedijk 73 box 601
8620 Nieuwpoort
Active since 20 April 2021
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 50 companies are registered at this address.
All companies at this address →Schiedel Metaloterm
€ 739,006 gross margin · 2024
International Investment Associates
GOLDPRINT
€ 6.9 million revenue · 2025
G.L. - METAL
LYONNAISE BELGIQUE - BELGIE
+45 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0465.291.083
- VAT number
- BE 0465.291.083
- Registered office
- Louizalaan 287 bus 16, 1050 Elsene
- Names & denominations
- Pharma Biotech Consultants Europe
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 20 January 1999
- Peppol
- Active · Active since 12 Dec 2025
- Activities · NACE
Ontwerpen van computerprogramma’s
Computeradviesbureaus
Ontwerpen en programmeren van computerprogramma's
Computerinfrastructuur, gegevensverwerking, hosting en aanverwante activiteiten
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen
Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten
Gegevensverwerking, webhosting en aanverwante activiteiten
Computerconsultancy-activiteiten